Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List
Insmed (Nasdaq: INSM) ranked No. 1 on Science's 2025 Top Biopharma Employers list, marking a record fifth consecutive year at the top, announced Oct. 23, 2025. The ranking is based on about 5,500 survey responses, primarily from North America (66%), Europe (20%), and Asia/Pacific Rim (9%). The company linked the recognition to a people-first culture and cited recent clinical successes and regulatory milestones as drivers of growth. Insmed highlighted strengths in corporate image, financial prowess, leadership, work culture, and intellectual challenge. More details and rankings are available on the publisher's feature and Insmed's culture page.
Insmed (Nasdaq: INSM) si è classificata al numero 1 nella lista dei Top Biopharma Employers 2025 di Science, segnando un quinto anno consecutivo in testa, comunicato il 23 ottobre 2025. La classifica si basa su circa 5.500 risposte a un sondaggio, principalmente provenienti da America del Nord (66%), Europa (20%) e Asia/Pacific Rim (9%). L'azienda ha collegato il riconoscimento a una cultura incentrata sulle persone e ha citato recenti successi clinici e traguardi regolatori come motori della crescita. Insmed ha evidenziato punti di forza nell'immagine aziendale, nella solidità finanziaria, nella leadership, nella cultura lavorativa e nella stimolante intellettuale. Maggiori dettagli e classifiche sono disponibili nella pagina dedicata del publisher e nella pagina sulla cultura di Insmed.
Insmed (Nasdaq: INSM) se ubicó en el Nº 1 en la lista de los Mejores Empleadores de Biofarmacia de Science 2025, marcando un quinto año consecutivo en la cima, anunciado el 23 de octubre de 2025. La clasificación se basa en unas 5.500 respuestas a la encuesta, principalmente de Norteamérica (66%), Europa (20%) y Asia/Pacífico (9%). La compañía vinculó el reconocimiento a una cultura centrada en las personas y citó éxitos clínicos recientes y hitos regulatorios como motores del crecimiento. Insmed destacó fortalezas en la imagen corporativa, la solvencia financiera, el liderazgo, la cultura de trabajo y el reto intelectual. Más detalles y clasificaciones están disponibles en la reseña del editor y en la página de cultura de Insmed.
Insmed (Nasdaq: INSM)가 Science의 2025년 최고 생물의약품 고용주 목록에서 1위를 차지했다고 2025년 10월 23일 발표했습니다. 이 순위는 약 5,500명의 설문 응답을 기반으로 하며, 주로 북미(66%), 유럽(20%), 아시아/태평양(9%)에서 수집되었습니다. 회사는 이 인정을 사람 우선 문화와 연관 지었고, 최근의 임상 성공과 규제 이정표를 성장의 원동력으로 언급했습니다. Insmed는 기업 이미지, 재무력, 리더십, 직장 문화, 지적 도전을 강점으로 강조했습니다. 더 많은 세부 정보와 순위는 발행인의 특집 기사와 Insmed의 문화 페이지에서 확인할 수 있습니다.
Insmed (Nasdaq : INSM) s’est classée numéro 1 sur la liste des Top Biopharma Employers 2025 de Science, marquant une cinquième année consécutive au sommet, a annoncé le 23 octobre 2025. Le classement se base sur environ 5 500 réponses à l’enquête, principalement en Amérique du Nord (66%), Europe (20%), et Asie/Pacifique (9%). L’entreprise a lié cette reconnaissance à une culture axée sur les personnes et a cité les récentes réussites cliniques et les jalons réglementaires comme moteurs de la croissance. Insmed a mis en avant les forces de son image d’entreprise, de sa solidité financière, de son leadership, de sa culture de travail et du défi intellectuel. Davantage de détails et de classements sont disponibles dans la rubrique de l’éditeur et sur la page culture d’Insmed.
Insmed (Nasdaq: INSM) belegte Rang 1 auf der Liste der Top Biopharma Employers 2025 von Science und markierte damit das rekordmäßige fünfte Jahr in Folge an der Spitze, wie am 23. Oktober 2025 bekannt gegeben wurde. Die Rangliste basiert auf rund 5.500 Umfrageteilnahmen, hauptsächlich aus Nordamerika (66%), Europa (20%) und Asien/Pazifik (9%). Das Unternehmen verknüpfte die Anerkennung mit einer Kultur, in der die Menschen an erster Stelle stehen, und nannte jüngste klinische Erfolge sowie regulatorische Meilensteine als Treiber des Wachstums. Insmed hob Stärken in der Unternehmensreputation, finanzieller Stärke, Führung, Arbeitskultur und intellektuelle Herausforderungen hervor. Weitere Details und Ranglisten finden Sie im Publikums-Feature des Verlags und auf Insmeds Kulturseite.
Insmed (ناسداك: INSM) احتلت المرتبة الأولى في قائمة أفضل أصحاب العمل في مجال الأدوية الحيوية 2025 من Science، وهو خامس عام مسجل في القمة على التوالي، وفق ما أعلن في 23 أكتوبر 2025. تستند التقييمات إلى نحو 5,500 من الردود على الاستطلاع، في الغالب من أمريكا الشمالية (66%)، أوروبا (20%)، وآسيا/منطقة المحيط الهادئ (9%). وربتت الشركة هذا التقدير بثقافة تضع الناس في المقام الأول وذكرت النجاحات السريرية الأخيرة والمعالم التنظيمية كمحركات للنمو. أبرزت Insmed نقاط القوة في الصورة المؤسسية، والقدرة المالية، والقيادة، وثقافة العمل، والتحدي الفكري. مزيد من التفاصيل والتقييمات متاحة في ملف المميزة للمحرر وعلى صفحة ثقافة Insmed.
Insmed (纳斯达克：INSM) 在 Science 的 2025 年最佳生物制药雇主榜单中排名第一，标志着连续第五年稳居第一，该信息于 2025 年 10 月 23 日发布。此次排名基于约 5,500 份问卷回复，主要来自 北美（66%）、欧洲（20%）、亚太（9%）。公司将这一认可与以人为本的文化联系起来，并将近期的临床成功与监管里程碑视为增长动力。Insmed 强调在企业形象、财务实力、领导力、工作文化和智力挑战方面的优势。更多细节和排名可在出版商专题以及 Insmed 的文化页查看。
- None.
- None.
—Insmed Leads Science Top Employers List for Fifth Year in a Row—
"It is an incredible privilege to see our organization recognized as the top employer in Science's annual survey for a record five consecutive years—something only achieved once before when the list first began," said Will Lewis, Chair and Chief Executive Officer of Insmed. "We are experiencing an extraordinary period of growth, driven by a series of clinical successes and regulatory milestones that support us in working toward our mission to transform the lives of patients with serious and rare diseases. This recognition reflects not only our deep commitment to advancing science, but also the passion and purpose that drive our work every day."
The 2025 survey results were based on approximately 5,500 responses from individuals located primarily across North America (
"Being recognized once again by Science as the top employer in the biopharma industry is a tremendous honor and a reflection of the people-first culture we continue to build at Insmed," said Nicole Schaeffer, Chief People Strategy Officer of Insmed. "By fostering an environment where collaboration meets flexibility, we enable our talented team to drive scientific breakthroughs on behalf of patients with serious diseases. I'm grateful to every colleague who makes Insmed such a special place to work."
The complete feature and company rankings can be accessed here. To learn more about Insmed's culture, please visit https://insmed.com/company/culture/.
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.
Headquartered in
Contact:
Investors:
Bryan Dunn
Vice President, Investor Relations
(646) 812-4030
investor.relations@insmed.com
Media:
Claire Mulhearn
Vice President, Corporate Communications
(862) 842-6819
media@insmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-ranks-no-1-on-sciences-2025-top-biopharma-employers-list-302593232.html
SOURCE Insmed Incorporated
FAQ
What recognition did Insmed (INSM) receive on October 23, 2025?
How many responses supported Science's 2025 ranking for Insmed (INSM)?
What regional breakdown did Science report for the 2025 employer survey that ranked Insmed (INSM)?
Does the press release say how the No. 1 ranking will affect Insmed (INSM) financials or stock price?
Which company strengths did Science highlight for Insmed (INSM) in the 2025 survey?
Where can investors and job candidates read the full Science 2025 rankings and learn about Insmed (INSM) culture?
